Beaumont Asset Management, L.L.C. Biogen Inc. Transaction History

Beaumont Asset Management, L.L.C.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	SELL	$193.77 - $244.14 $236,786 - $298,339	-1,222 Closed	0 $0
Q4 2021 Jan 25, 2022	BUY	$223.92 - $287.77 $18,137 - $23,309	81 Added 7.1%	1,222 $293,000
Q3 2021 Oct 20, 2021	BUY	$282.99 - $369.05 $11,602 - $15,131	41 Added 3.73%	1,141 $323,000
Q2 2021 Aug 12, 2021	SELL	$259.0 - $414.71 $189,847 - $303,982	-733 Reduced 39.99%	1,100 $381,000
Q1 2021 Apr 29, 2021	BUY	$242.95 - $284.63 $5,101 - $5,977	21 Added 1.16%	1,833 $513,000
Q4 2020 Feb 04, 2021	SELL	$236.26 - $355.63 $226,573 - $341,049	-959 Reduced 34.61%	1,812 $443,000
Q3 2020 Oct 14, 2020	SELL	$264.77 - $305.71 $31,242 - $36,073	-118 Reduced 4.08%	2,771 $786,000
Q2 2020 Aug 06, 2020	BUY	$258.66 - $342.55 $12,157 - $16,099	47 Added 1.65%	2,889 $772,000
Q1 2020 Apr 21, 2020	SELL	$268.85 - $341.04 $16,937 - $21,485	-63 Reduced 2.17%	2,842 $899,000
Q4 2019 Jan 29, 2020	BUY	$220.06 - $304.07 $639,274 - $883,323	2,905 New	2,905 $862,000

1,035

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $23B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Beaumont Asset Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Beaumont Asset Management, L.L.C. with notifications on news.